FDA: Eylea Approval Expanded to Include Diabetic Retinopathy

Among people with diabetic macular edema

WEDNESDAY, March 25, 2015 (HealthDay News) -- U.S. Food and Drug Administration approval of Eylea (aflibercept) has been expanded to treat diabetic retinopathy among people with diabetic macular edema, the agency said Wednesday in a news release.

The injected drug Eylea is intended to be used in tandem with appropriate therapies to control blood glucose, blood pressure, and cholesterol, the FDA said.

The drug's safety and effectiveness were evaluated in clinical studies involving 679 people. The most common side effects included bleeding of the conjunctiva, eye pain, cataracts, floaters, and increased intraocular pressure.

Eylea was first approved in 2012 to treat wet age-related macular degeneration, and also was sanctioned to treat diabetic macular edema and macular edema secondary to retinal vein occlusions.

The drug is marketed by Regeneron Pharmaceuticals, based in Tarrytown, N.Y.

More Information

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on March 25, 2015

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ